|
|
Volumn 347, Issue 6219, 2015, Pages 226-229
|
|
The cancer stem cell gamble
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
DEFACTINIB;
REPARIXIN;
TAREXTUMAB;
VISMODEGIB;
ANTINEOPLASTIC AGENT;
ENZYME INHIBITOR;
FOCAL ADHESION KINASE;
CANCER;
CELLS AND CELL COMPONENTS;
CHEMOTHERAPY;
DRUG;
ARTICLE;
BASAL CELL CARCINOMA;
BREAST METASTASIS;
CANCER CHEMOTHERAPY;
CANCER PATIENT;
CANCER STEM CELL;
CARCINOGENESIS;
HUMAN;
LUNG CANCER;
MESOTHELIOMA;
PANCREAS CANCER;
PATIENT SAFETY;
PHASE 2 CLINICAL TRIAL (TOPIC);
PRIORITY JOURNAL;
SCIENTIST;
TUMOR SEEDING;
ANTAGONISTS AND INHIBITORS;
CELL COUNT;
CLINICAL TRIAL (TOPIC);
DRUG EFFECTS;
MOLECULARLY TARGETED THERAPY;
NEOPLASMS;
PATHOLOGY;
PHYSIOLOGY;
SIGNAL TRANSDUCTION;
MASSACHUSETTS;
UNITED STATES;
ANTINEOPLASTIC AGENTS;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
CELL COUNT;
CLINICAL TRIALS AS TOPIC;
ENZYME INHIBITORS;
FOCAL ADHESION PROTEIN-TYROSINE KINASES;
HUMANS;
MOLECULAR TARGETED THERAPY;
NEOPLASMS;
NEOPLASTIC STEM CELLS;
SIGNAL TRANSDUCTION;
|
|
EID: 84922480805
PISSN: 00368075
EISSN: 10959203
Source Type: Journal
DOI: 10.1126/science.347.6219.226 Document Type: Article |
|
Times cited : (149)
|
|
References (0)
|